A total of 265 patients with metastatic breast cancer were included in a multicentric randomized clinical study with the FAC with or without lonidamine (LND). Objective clinical responses (CR+PR) were observed in 46.7% of the FAC-treated patients (group A) and in 62.1% of the FAC+LND-treated patients (group B) (p = 0.002). Time to progression was 6.3 versus 9.2 months (p = 0.003) and median survival 17.9 versus 18.7 months (N.S.) but in the postmenopausal subgroup patients the median survival was 14.8 versus 18.9 months (p 0.018) for group A versus B, respectively. Group B patients showed no significant increase of toxicity, except for myalgia (WHO grade ≥2 in 24.8% of the LND-heated patients) and epigastralgia (WHO grade ≥2 in 15.0% of the LND-treated patients). These results demonstrate that LND can potentiate the FAC regimen and suggest the need for further investigations of LND combined with other polychemotherapy regimens in breast cancer.
|Number of pages||8|
|Journal||International Journal of Oncology|
|Publication status||Published - 1994|
- advanced breast cancer
- FAC chemotherapy
ASJC Scopus subject areas
- Cancer Research